TNSN97109A1 - Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire - Google Patents

Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Info

Publication number
TNSN97109A1
TNSN97109A1 TNTNSN97109A TNSN97109A TNSN97109A1 TN SN97109 A1 TNSN97109 A1 TN SN97109A1 TN TNSN97109 A TNTNSN97109 A TN TNSN97109A TN SN97109 A TNSN97109 A TN SN97109A TN SN97109 A1 TNSN97109 A1 TN SN97109A1
Authority
TN
Tunisia
Prior art keywords
virus
avian
vector
vaccine
infectious laryngotracheitis
Prior art date
Application number
TNTNSN97109A
Other languages
English (en)
French (fr)
Inventor
Audonnet Jean-Christophe
Bublot Michel
Riviere Michel
Original Assignee
Rhone Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Merieux filed Critical Rhone Merieux
Publication of TNSN97109A1 publication Critical patent/TNSN97109A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TNTNSN97109A 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire TNSN97109A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9608243A FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Publications (1)

Publication Number Publication Date
TNSN97109A1 true TNSN97109A1 (fr) 2005-03-15

Family

ID=9493649

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97109A TNSN97109A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Country Status (13)

Country Link
US (1) US6153199A (enExample)
EP (1) EP0914458A1 (enExample)
JP (1) JP2000512844A (enExample)
AR (1) AR008620A1 (enExample)
AU (1) AU739374B2 (enExample)
CO (1) CO4700303A1 (enExample)
FR (1) FR2750866B1 (enExample)
ID (1) ID18351A (enExample)
MA (1) MA24222A1 (enExample)
PE (1) PE52599A1 (enExample)
TN (1) TNSN97109A1 (enExample)
WO (1) WO1997049826A1 (enExample)
ZA (1) ZA975618B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913751B2 (en) 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
WO1999018215A1 (en) 1997-10-03 1999-04-15 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
AR031405A1 (es) * 2000-11-21 2003-09-24 Wyeth Corp Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo
JP2002356441A (ja) * 2001-03-15 2002-12-13 Akzo Nobel Nv 組換え伝染性喉頭気管炎ウイルスワクチン
US7314715B2 (en) * 2001-06-14 2008-01-01 Schering-Plough Animal Health Corporation Recombinant avian herpesvirus useful in vaccine production
EP2022799A2 (en) 2001-11-16 2009-02-11 Biogen Idec Inc. Polycistronic expression of antibodies
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
EP1689858B1 (en) 2003-11-13 2013-05-15 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
MXPA06009452A (es) 2004-02-19 2007-03-15 Univ Alberta Polimorfismos del promotor de leptin y sus usos.
SI1881845T1 (sl) 2005-04-25 2010-06-30 Merial Ltd Cepiva proti virusu Nipah
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
JP5797636B2 (ja) 2009-04-03 2015-10-21 メリアル リミテッド ニューカッスル病ウイルスをベクターとするトリワクチン
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
WO2011090708A2 (en) 2009-12-28 2011-07-28 Merial Limited Recombinant ndv antigen and uses thereof
WO2012018813A2 (en) * 2010-08-02 2012-02-09 University Of Georgia Research Foundation, Inc. Modified infectious laryngotracheitis virus (iltv) and uses thereof
JP5913316B2 (ja) 2010-08-31 2016-04-27 メリアル リミテッド ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
AU2012240246A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
KR102007444B1 (ko) 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
US10166188B2 (en) 2011-08-12 2019-01-01 Merial, Inc. Method for vacuum-assisted preservation of biologics including vaccines
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
WO2014081958A1 (en) 2012-11-21 2014-05-30 Cardiomems, Inc. Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment
HK1216006A1 (zh) 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
US9198908B2 (en) 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
EP2845904A1 (en) * 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
US10010499B2 (en) 2014-11-03 2018-07-03 Merial Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2016210094A1 (en) 2015-06-23 2016-12-29 Merial, Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748631B1 (en) * 1988-09-13 2006-02-08 Mérial Viral vaccines
WO1992003554A1 (en) * 1990-08-24 1992-03-05 Arthur Webster Pty. Ltd. Infectious laryngotracheitis virus vaccine
WO1993025655A1 (en) * 1992-06-12 1993-12-23 Genencor International, Inc. Enzymatic compositions and methods for producing stonewashed look on indigo-dyed denim fabric
AU2946395A (en) * 1994-06-30 1996-01-25 Board of Regents of the University of Illinois, The Recombinant infectious laryngotracheitis virus and vaccine
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
WO1996029396A1 (en) * 1995-03-23 1996-09-26 Syntro Corporation Recombinant infectious laryngotracheitis virus and uses thereof

Also Published As

Publication number Publication date
AR008620A1 (es) 2000-02-09
JP2000512844A (ja) 2000-10-03
WO1997049826A1 (fr) 1997-12-31
US6153199A (en) 2000-11-28
FR2750866A1 (fr) 1998-01-16
AU3448797A (en) 1998-01-14
PE52599A1 (es) 1999-07-16
ID18351A (id) 1998-04-02
AU739374B2 (en) 2001-10-11
CO4700303A1 (es) 1998-12-29
EP0914458A1 (fr) 1999-05-12
FR2750866B1 (fr) 1998-11-27
MA24222A1 (fr) 1997-12-31
ZA975618B (en) 1998-12-28

Similar Documents

Publication Publication Date Title
TNSN97109A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
TNSN98015A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngottracheite infectieuse aviaire
EP1403375A3 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpès aviaire
TNSN97207A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
AU711815B2 (en) Recombinant herpesvirus of turkeys and uses thereof
HUP9902790A2 (hu) Madarakban alkalmazható polinukleotid-vakcinakészítmények
HUT67138A (en) Attenvated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
EP1298139A3 (en) Avian herpes virus-based recombinant infectious bursal disease vaccine
EP0728842A2 (fr) Vaccin vivant recombinant aviaire à base de virus herpès aviaire, notamment contre la maladie de gumboro
US5961982A (en) Recombinant herpesvirus of turkeys and uses thereof
AU3891897A (en) A method for generating birnavirus from synthetic rna transcripts
CA2366541A1 (en) Novel recombinant and mutant herpesviruses
AU696247B2 (en) Recombinant fowlpox viruses and uses thereof
WO1994019014A9 (en) Recombinant fowlpox virus s-fpv-043 and uses thereof
CA2223591A1 (en) Recombinant fowlpox viruses and uses thereof
DE68912478D1 (de) Rekombinantes Marek-Krankheitsvirus, Verfahren zu seiner Herstellung, und Vakzine.
CA2478081A1 (en) Multiple and multivalent dna vaccines in ovo
AU753963B2 (en) Processes for preparation of Marek's disease virus using continuous mammalian cell lines
WO2000074630A3 (en) Dna vaccine for protecting an avian against infectious bursal disease virus
EP0365349A1 (en) Avipox virus promoter
MX9702769A (es) Mejoras en una linea de celulas sustentable o estable para la produccion de vacunas para la enfermedad de marek.
ECSP972164A (es) Vacunas de uso aviario a base de virus de laringotraqueitis infecciosa
AU727278B2 (en) Recombinant fowlpox viruses and uses thereof II
WO1999055860A8 (en) Host-encoded protein expressed on marek's disease (mdv)-infected cells and antibody thereto
TH25170A (th) รีคอมบิแนนท์วัคซีนของนกชนิดที่มีชีวิตโดยใช้เฮอร์ปีส์ไวรัสของนกเป็นเวกเตอร์